Targeted Nanomedicine for the modulation of pancreatic tumor immune surveillance

作者
Kashyap, Vivek Kumar,Chauhan, Neeraj,Sikander, Mohammed,Ghali, Eswara N. H. K.,Tiwari, Rahul,Malik, Shabnam,Khan, Sheema,Hafeez, Bilal B.,Yallapu, Murali M,Chauhan, Subhash C.
出处
期刊:The University of Texas Rio Grande Valley - ScholarWorks @ UTRGV [The University of Texas Rio Grande Valley]
摘要

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer, characterized by a dismal 5-year overall survival rate, primarily due to the lack of early detection and limited effective treatment options available. Gemcitabine (GEM) is the most effective therapy for PanCa, but it only offers a marginal survival benefit of 6 months. A combination of Paclitaxel (PTX) albumin nano-formulation (Abraxane) and Gemcitabine has shown marginal improvement in pancreatic cancer treatment. This poor treatment response has been associated with desmoplastic stroma, microbiome effects, altered tumor microenvironment (TME), suppressive immune cells and PDAC-specific signaling pathways. Our research has demonstrated that MUC13 is highly overexpressed in PanCa and is associated with cancer progression and metastases. Considering these facts, we have generated an MUC13 antibody targeted nanoparticle formulation for tumor specific targeted delivery of paclitaxel using a multi-layered Pluronic F127 and polyvinyl alcohol stabilized and poly-L-lysine coated poly(lactic-co-glycolic acid) nanoparticles (PPNPs) to improve therapeutic outcome of PanCa therapy. Our MUC13-targeted PPNPs (MUC13-PPNPs) showed enhanced cellular uptake of MUC13-PPNPs formulation in HPAF-II (MUC13+) compared with Panc-1 (MUC13­) PanCa cells as determined by immunofluorescence. Further, our novel formulation effectively inhibits growth and metastatic phenotypes in MUC13+ cells as compared with MUC13- cells of PanCa in vitro model systems. In our PanCa xenograft mouse model (HPAF-II + stromal cells), we found that PPNPs alone significantly inhibited the growth of the tumor (P < 0.05 when compared with control (PLGA) and treatment group PTX. Furthermore, the tumor volume of the MUC13-PPNPs group was not only highly significantly lower than the control PLGA and PTX (P < 0.05), but also lower than PPNPs alone group (P < 0.05) or control (P < 0.05). Our findings also demonstrated that PPNPs/MUC13-PPNPs synergize GEM therapy response in vitro and in vivo mouse models. Further, tumor tissue treated with PPNPs/MUC13-PPNPs demonstrate the downregulated expression of sonic hedgehog (SHH) and other oncogenic signaling axis determined by qPCR ,Western blot s and immunofluorescence analyses. Additionally, our nano formulation effectively reduced the tumor volume in syngeneic orthotopic xenograft mouse model involving injection of KPC-Luc in C57Black/6 mice and target tumor-associated macrophages (TAM) by repolarizing M2 into M1 phenotype via inhibiting expression of M2 markers and an increase in M1 markers. In conclusion, we observed that our novel formulation has high therapeutic ability for achieving pancreatic tumor specific delivery PTX, synergize GEM therapy response and altered the tumor immune surveillance mechanisms. Thus, this unique approach can effectively enhance therapeutic efficacy main line chemotherapies and immune checkpoint immunotherapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
任驰骋完成签到,获得积分10
1秒前
xiedi的应助被liu采纳,获得10
1秒前
1秒前
虚幻的靖儿完成签到 ,获得积分10
1秒前
suxinfeng完成签到,获得积分10
3秒前
搜集达人的应助被占博涛采纳,获得10
4秒前
哈47发布了新的文献求助10
4秒前
欢喜的楷瑞完成签到,获得积分10
4秒前
jackie完成签到,获得积分10
5秒前
无极微光的应助被叶95采纳,获得20
5秒前
CarryLJR的应助被Aoooo采纳,获得10
5秒前
shuyiWang发布了新的文献求助10
5秒前
百事可爱完成签到 ,获得积分10
6秒前
长青关注了科研通微信公众号
6秒前
今后的应助被xiaolong采纳,获得10
7秒前
奋斗的西装完成签到,获得积分10
8秒前
9秒前
清辉影的应助被XPR采纳,获得10
9秒前
小浅浅发布了新的文献求助10
9秒前
10秒前
科目三的应助被yuyuhong采纳,获得10
10秒前
麻瓜完成签到,获得积分10
10秒前
叫我老贾就好了完成签到,获得积分10
11秒前
丘比特的应助被科研通管家采纳,获得10
11秒前
田様的应助被科研通管家采纳,获得10
12秒前
英姑的应助被科研通管家采纳,获得10
12秒前
12秒前
慕青的应助被科研通管家采纳,获得10
12秒前
12秒前
12秒前
852的应助被科研通管家采纳,获得10
12秒前
velsaber的应助被科研通管家采纳,获得10
12秒前
打打的应助被科研通管家采纳,获得10
13秒前
思源的应助被科研通管家采纳,获得10
13秒前
彭于晏的应助被科研通管家采纳,获得10
13秒前
我是老大的应助被科研通管家采纳,获得10
13秒前
orixero的应助被科研通管家采纳,获得10
13秒前
安彩青完成签到 ,获得积分10
13秒前
Maestro_S的应助被科研通管家采纳,获得10
13秒前
LA完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614